Emalex Biosciences Acquired by Teva

Emalex Biosciences Acquired by Teva

by John Conrad | Apr 29, 2026 | Member News

Emalex Biosciences has been acquired by Teva Pharmaceutical Industries, marking a significant milestone for the company and its lead neuroscience program.

The acquisition is centered on Emalex's first-in-class, NDA-ready therapy targeting Tourette syndrome and related neuropsychiatric conditions. After years of focused development, the program now moves into the hands of a global pharmaceutical company with the scale and infrastructure to advance it through regulatory review and, ultimately, to patients.

For Emalex, this moment reflects the successful translation of innovative science into a late-stage asset with real clinical potential. The company's work developing selective dopamine D1 receptor antagonists has positioned it at the forefront of a new approach to treating complex neurological disorders.

The deal also highlights the role of emerging biotech companies in driving early innovation-building the scientific and clinical foundation that larger organizations can then help bring across the finish line.

With this acquisition, Emalex's science takes an important step forward, moving closer to delivering a new treatment option for patients who have long faced limited choices.